News

The Lancet1d
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular ...
In the randomised phase 3 TRIBE study, 1 first-line treatment of patients with metastatic colorectal cancer with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab ...
The Lancet3d
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled ...
The Scandinavian HYPO-RT-PC randomised phase 3 trial showed that ultra-hypofractionated radiotherapy was non-inferior to conventional fractionation in terms of failure-free survival with similar late ...